IN2013MN02014A - - Google Patents
Download PDFInfo
- Publication number
- IN2013MN02014A IN2013MN02014A IN2014MUN2013A IN2013MN02014A IN 2013MN02014 A IN2013MN02014 A IN 2013MN02014A IN 2014MUN2013 A IN2014MUN2013 A IN 2014MUN2013A IN 2013MN02014 A IN2013MN02014 A IN 2013MN02014A
- Authority
- IN
- India
- Prior art keywords
- nampt
- antidotes
- inhibition
- compositions
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161483937P | 2011-05-09 | 2011-05-09 | |
US201161512546P | 2011-07-28 | 2011-07-28 | |
PCT/US2011/050303 WO2012154194A1 (en) | 2011-05-09 | 2011-09-02 | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt) |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2013MN02014A true IN2013MN02014A (de) | 2015-06-12 |
Family
ID=44681420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2014MUN2013 IN2013MN02014A (de) | 2011-05-09 | 2011-09-02 |
Country Status (13)
Country | Link |
---|---|
US (5) | US9555039B2 (de) |
JP (2) | JP5872027B2 (de) |
KR (1) | KR20140038443A (de) |
CN (2) | CN103874686B (de) |
AR (1) | AR082889A1 (de) |
AU (1) | AU2011367809B2 (de) |
BR (1) | BR112013028877A2 (de) |
CA (1) | CA2834745A1 (de) |
IN (1) | IN2013MN02014A (de) |
MX (1) | MX347459B (de) |
RU (1) | RU2617643C2 (de) |
TW (1) | TW201245188A (de) |
WO (1) | WO2012154194A1 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011295724B2 (en) | 2010-09-03 | 2016-05-12 | Forma Tm, Llc | 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as NAMPT inhibitors for therapy of diseases such as cancer |
BR112013004773B1 (pt) | 2010-09-03 | 2022-05-31 | Forma Tm, Llc | Compostos, seus usos, e composições para a inibição de nampt |
CN103874686B (zh) | 2011-05-09 | 2016-08-17 | 福马Tm有限责任公司 | 用于抑制烟酰胺磷酸核糖基转移酶(nampt)的哌啶衍生物和组合物 |
WO2013127268A1 (en) * | 2012-03-02 | 2013-09-06 | Genentech,Inc. | Amido-benzyl sulfone and sulfonamide derivatives |
US10696692B2 (en) | 2012-03-02 | 2020-06-30 | Forma Tm, Llc | Amido-benzyl sulfone and sulfoxide derivates |
ES2620668T3 (es) | 2012-03-02 | 2017-06-29 | Genentech, Inc. | Derivados de amidas y sulfonamidas amido espirocíclicas |
CN104428301A (zh) | 2012-05-11 | 2015-03-18 | 艾伯维公司 | Nampt抑制剂 |
JP6510556B2 (ja) | 2014-04-18 | 2019-05-08 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | キノキサリン化合物及びその使用 |
JP2017521426A (ja) | 2014-07-23 | 2017-08-03 | オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited | Nampt抑制物質としての4,5−ジヒドロイソオキサゾール誘導体 |
CA2974078A1 (en) * | 2015-01-20 | 2016-07-28 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof |
MX2018013433A (es) | 2016-05-02 | 2019-07-18 | Univ Michigan Regents | Piperidinas como inhibidores de menina. |
AU2017345262A1 (en) | 2016-10-18 | 2019-06-06 | Seagen Inc. | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors |
JP2020515571A (ja) * | 2017-03-31 | 2020-05-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 共有結合性メニン阻害剤としてのピペリジン |
SG11201909563VA (en) | 2017-04-27 | 2019-11-28 | Seattle Genetics Inc | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
JP2019137638A (ja) * | 2018-02-09 | 2019-08-22 | アピオン・ジャパン有限会社 | 新規nampt阻害剤およびそれを含有する抗腫瘍剤、新規nampt阻害剤のスクリーニング方法、新規naprt阻害剤およびそれを含有する抗腫瘍剤、新規naprt阻害剤のスクリーニング方法、腫瘍細胞に対して正常細胞の割合を増やすための方法、並びに抗腫瘍剤の処方を補助する方法 |
US20220160688A1 (en) * | 2019-03-20 | 2022-05-26 | The Johns Hopkins University | Inhibition of nampt and/or sarm1 for the treatment of axonal degradation |
WO2021066573A1 (ko) * | 2019-10-04 | 2021-04-08 | 파렌키마바이오텍 주식회사 | 신규 화합물 및 이의 자가면역질환 치료 용도 |
WO2022109285A1 (en) * | 2020-11-20 | 2022-05-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and materials for inhibiting nicotinamide phosphoribosyltransferase activity |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2777159B2 (ja) * | 1988-12-22 | 1998-07-16 | エーザイ株式会社 | 環状アミン誘導体を含有する医薬 |
DE19624704A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalkansäureamide |
DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
DE19756235A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide |
DE19756261A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide |
DE19756236A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
DE19756212A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
EP1031564A1 (de) | 1999-02-26 | 2000-08-30 | Klinge Pharma GmbH | Hemmer der Nicotinamidmonononukleotide-Bildung und deren Verwendung zur Krebstherapie |
US6506901B2 (en) | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
WO2002100846A1 (en) | 2001-06-11 | 2002-12-19 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
EP1348434A1 (de) | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Verwendung von Pyridylamiden als Inhibitoren von Angiogenese |
NZ537330A (en) | 2002-05-31 | 2007-04-27 | Takeda Chemical Industries Ltd | Piperidine derivative, process for producing the same, and use |
SG156524A1 (en) * | 2002-06-20 | 2009-11-26 | Biovitrum Ab Publ | New compounds useful for the treatment of obesity, type ii diabetes and cns disorders |
US7491827B2 (en) | 2002-12-23 | 2009-02-17 | Millennium Pharmaceuticals, Inc. | Aryl sulfonamides useful as inhibitors of chemokine receptor activity |
CA2669736C (en) * | 2005-11-03 | 2017-02-21 | Chembridge Research Laboratories, Inc. | Heterocyclic compounds as tyrosine kinase modulators |
CN101007814A (zh) * | 2006-01-27 | 2007-08-01 | 上海恒瑞医药有限公司 | 吡咯并六元杂环化合物及其在医药上的用途 |
WO2008026018A1 (en) | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
US8450348B2 (en) | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
CN102639503B (zh) * | 2009-06-09 | 2014-10-15 | 顶标公司 | 作为烟酰胺磷酸核糖基转移酶抑制剂的吡啶基衍生物 |
JP5881705B2 (ja) * | 2010-09-03 | 2016-03-09 | フォーマ ティーエム, エルエルシー. | Namptの阻害のための新規化合物及び組成物 |
BR112013004773B1 (pt) * | 2010-09-03 | 2022-05-31 | Forma Tm, Llc | Compostos, seus usos, e composições para a inibição de nampt |
AU2011295724B2 (en) | 2010-09-03 | 2016-05-12 | Forma Tm, Llc | 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as NAMPT inhibitors for therapy of diseases such as cancer |
UY33726A (es) | 2010-11-15 | 2012-06-29 | Abbott Lab | Inhibidores de nampt y rock |
JP5978293B2 (ja) * | 2011-05-04 | 2016-08-24 | フォーマ ティーエム, エルエルシー. | Namptを阻害するための新規な化合物および組成物 |
CN103874686B (zh) | 2011-05-09 | 2016-08-17 | 福马Tm有限责任公司 | 用于抑制烟酰胺磷酸核糖基转移酶(nampt)的哌啶衍生物和组合物 |
JP2015508785A (ja) | 2012-03-02 | 2015-03-23 | ジェネンテック, インコーポレイテッド | ピリジニル及びピリミジニルスルホキシド及びスルホン誘導体 |
US10696692B2 (en) | 2012-03-02 | 2020-06-30 | Forma Tm, Llc | Amido-benzyl sulfone and sulfoxide derivates |
ES2620668T3 (es) | 2012-03-02 | 2017-06-29 | Genentech, Inc. | Derivados de amidas y sulfonamidas amido espirocíclicas |
-
2011
- 2011-09-02 CN CN201180072205.5A patent/CN103874686B/zh not_active Expired - Fee Related
- 2011-09-02 IN IN2014MUN2013 patent/IN2013MN02014A/en unknown
- 2011-09-02 JP JP2014510294A patent/JP5872027B2/ja not_active Expired - Fee Related
- 2011-09-02 KR KR1020137032144A patent/KR20140038443A/ko not_active Application Discontinuation
- 2011-09-02 AR ARP110103222A patent/AR082889A1/es unknown
- 2011-09-02 CN CN201610403792.6A patent/CN106083886A/zh active Pending
- 2011-09-02 WO PCT/US2011/050303 patent/WO2012154194A1/en active Application Filing
- 2011-09-02 TW TW100131859A patent/TW201245188A/zh unknown
- 2011-09-02 RU RU2013154416A patent/RU2617643C2/ru active IP Right Revival
- 2011-09-02 CA CA2834745A patent/CA2834745A1/en not_active Abandoned
- 2011-09-02 MX MX2013013041A patent/MX347459B/es active IP Right Grant
- 2011-09-02 US US14/115,849 patent/US9555039B2/en active Active
- 2011-09-02 AU AU2011367809A patent/AU2011367809B2/en not_active Ceased
- 2011-09-02 BR BR112013028877A patent/BR112013028877A2/pt not_active Application Discontinuation
-
2016
- 2016-01-07 JP JP2016001874A patent/JP2016104787A/ja not_active Withdrawn
-
2017
- 2017-01-30 US US15/419,727 patent/US20170137441A1/en not_active Abandoned
-
2018
- 2018-06-07 US US16/002,651 patent/US20190031686A1/en not_active Abandoned
-
2020
- 2020-09-16 US US17/022,906 patent/US11479564B2/en active Active
-
2022
- 2022-09-09 US US17/941,061 patent/US20230110003A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2013013041A (es) | 2013-12-02 |
US11479564B2 (en) | 2022-10-25 |
CN103874686A (zh) | 2014-06-18 |
RU2013154416A (ru) | 2015-06-20 |
US9555039B2 (en) | 2017-01-31 |
AR082889A1 (es) | 2013-01-16 |
US20140248240A1 (en) | 2014-09-04 |
CA2834745A1 (en) | 2012-11-15 |
JP5872027B2 (ja) | 2016-03-01 |
TW201245188A (en) | 2012-11-16 |
AU2011367809B2 (en) | 2017-04-27 |
RU2617643C2 (ru) | 2017-04-25 |
US20170137441A1 (en) | 2017-05-18 |
JP2014516951A (ja) | 2014-07-17 |
MX347459B (es) | 2017-04-26 |
WO2012154194A1 (en) | 2012-11-15 |
KR20140038443A (ko) | 2014-03-28 |
CN106083886A (zh) | 2016-11-09 |
BR112013028877A2 (pt) | 2017-01-31 |
AU2011367809A1 (en) | 2013-11-21 |
US20190031686A1 (en) | 2019-01-31 |
US20230110003A1 (en) | 2023-04-13 |
CN103874686B (zh) | 2016-08-17 |
US20210246147A1 (en) | 2021-08-12 |
JP2016104787A (ja) | 2016-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2013MN02014A (de) | ||
IN2013CN02463A (de) | ||
MX2013012760A (es) | Nuevos compuestos y composiciones para la inhibicion de nampt. | |
MX342838B (es) | Compuestos y composiciones de guanidina para la inhibicion de nampt. | |
PH12015502097A1 (en) | Novel compounds and compositions for inhibition of fasn | |
IN2014MN02496A (de) | ||
MX342481B (es) | Nuevos compuestos y composiciones para la inhibicion de nampt. | |
CR20140042A (es) | Indazoles | |
IN2014MN02459A (de) | ||
PH12015500008B1 (en) | Dimethyl-benzoic acid compounds | |
EP2590649A4 (de) | Verfahren zur synthese substituierter morphinane | |
GEP20156372B (en) | Pyridazinone compounds and their use as daao inhibitors | |
IN2014MN01521A (de) | ||
CR20130501A (es) | Derivados novedosos de cefalosporinas y composiciones farmacéuticas de estos | |
MY166449A (en) | Pharmaceutical composition of rosuvastatin calcium | |
MX355415B (es) | Composiciones y metodos para tratar enfermedades y trastornos que son modulados por una vía de transducción de señales. | |
MX2013013262A (es) | Derivados de ciclododecadienona como ingredientes de perfumado. | |
MX2016007186A (es) | Nuevo procedimiento de sintesis de la agomelatina. | |
IN2015DN02514A (de) | ||
NZ751449A (en) | Novel compounds and compositions for inhibition of fasn | |
MY161361A (en) | Substituted phenyl compounds | |
IN2013CN00515A (de) | ||
CO6680719A2 (es) | Derivados de carboxamida para la inhibición de nampt | |
IN2013MU01256A (de) | ||
JO3085B1 (ar) | طريقة جديدة لتصنيع أجوميلاتين |